Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Jun 16, 2015
SAN DIEGO, June 16, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer, has decided to leave the company after nearly 18 years of service to pursue another opportunity in the biotechnology industry. Mr. Hoffman is expected to remain in hi...
Jun 4, 2015
WOODCLIFF LAKE, N.J. and SAN DIEGO, June 4, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the following poster regarding lorcaserin HCl will be presented at American Diabetes Association's 75th Scientific Sessions taking place June 5-9, 2015, in Boston, Massachusetts: Impact of ...
May 26, 2015
SAN DIEGO, May 26, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Jefferies 2015 Global Healthcare Conference on Monday, June 1, 2015, at 10:30 a.m. Eastern Time (7:30 a.m. Pacific Time), at the Grand Hyatt in New York, New York. ...
May 14, 2015
WOODCLIFF LAKE, N.J., and SAN DIEGO, May 14, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that lorcaserin HCl data will be presented at the following medical meetings: American Thoracic Society International Conference taking place in Denver, Colorado, May 15-20, 2015Lorcaserin for Smokin...
May 11, 2015
SAN DIEGO, May 11, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2015. "We are pleased with the progress we have made thus far in 2015, including the approval and launch of BELVIQ in South Korea, our entry into a collabora...
May 11, 2015
SAN DIEGO, May 11, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its subsidiary, Arena Pharmaceuticals GmbH, and Roivant Sciences Ltd., have entered into a Development, Marketing and Supply Agreement for nelotanserin, Arena's internally discovered inverse agonist of the 5-HT2A receptor. The agreement grants Ro...
May 8, 2015
SAN DIEGO, May 8, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13, 2015, at 9:20 a.m. Pacific Time (12:20 p.m. Eastern Time), at the Encore at the Wynn in Las ...
May 7, 2015
SAN DIEGO, May 7, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Monday, May 11, 2015, to provide a corporate update and discuss first quarter 2015 financial results. Arena will release its financial results after t...
Apr 29, 2015
SAN DIEGO, April 29, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced favorable results from a Phase 1 single-ascending dose clinical trial of APD371, a highly selective and potent agonist of the cannabinoid 2 (CB2) receptor currently in development for the treatment of pain and potentially fibrotic diseases. T...
Apr 10, 2015
WOODCLIFF LAKE, N.J. and SAN DIEGO, Calif., April 10, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as comp...
Apr 9, 2015
SAN DIEGO, April 9, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015, at 12:50 p.m. Eastern Time (9:50 a.m. Pacific Time), at the Westin Grand Central Hotel in New York...
Apr 7, 2015
SAN DIEGO and WOODCLIFF LAKE, N.J., April 7, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc., announced today that the US Patent and Trademark Office granted Arena US Patent No. 8,999,970, which describes a method for selecting appropriate patients based on renal function for BELVIQ® (lorcaserin HCl), a serotonin...
Mar 2, 2015
SAN DIEGO, March 2, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2014. "2014 was a pivotal year for Arena, marked by the advancement of multiple development programs and the growth of sales of BELVIQ," s...
Feb 23, 2015
SAN DIEGO, Feb. 23, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Monday, March 2, 2015, to provide a corporate update and discuss fourth quarter and full year 2014 financial results. Arena will release its financi...
Feb 18, 2015
SAN DIEGO, Feb. 18, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 2015 RBC Capital Markets Healthcare Conference on Tuesday, February 24, 2015, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time), at The New York Palace Hotel in New Yor...
Page: First Previous
...
...
Next Last
 
= add release to Briefcase